ReNeuron Group (RENE)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

   Trade now with Barclays Stockbrokers   Trade now with Barclays   Sponsored by Barclays Stockbrokers

 60.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 205.00
  • 52 Week Low: 53.50
  • Currency: UK Pounds
  • Shares Issued: 31.65m
  • Volume: 2,000
  • Market Cap: £19.15m
  • RiskGrade: 282
  • Beta: 0.21

ReNeuron Group Overview

ReNeuron Group is in the pharma and biotech sector and is currently trading at 60.50p per share. In the last year ReNeuron Group's share price has ranged from 53.50p to 205.00p and brokers are currently rating this stock as 'strong buy'.

1 Day Chart (16-11-2018)

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -50950.0% -1290.5%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 478.6 8.0
Pr/Book 0.5  
Latest F'cast
Revenue -20.0% 5857.6%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

ReNeuron Group Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-14 0.02 (7.82) (16.65)p n/a n/a n/a n/a 0.0%
31-Mar-15 0.03 (10.30) (50.00)p n/a n/a n/a n/a 0.0%
31-Mar-16 0.03 (12.85) (40.00)p n/a n/a n/a n/a 0.0%
31-Mar-17 0.05 (18.16) (4,920.00)p n/a n/a n/a n/a 0.0%
31-Mar-18 0.04 (20.97) (55.70)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

ReNeuron Group Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-19 2.38 (30.75) (84.10)p n/a n/a n/a n/a 0.0%
31-Mar-20 0.52 (27.42) (75.54)p n/a n/a n/a n/a 0.0%

Copyright © 2018 FactSet Research Systems Inc. All rights reserved.

Latest ReNeuron Group Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

ReNeuron Group Market Data

Currency UK Pounds
Share Price 60.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 205.00
52 Week Low 53.50
Volume 2,000
Shares Issued 31.65m
Market Cap £19.15m
Beta 0.21
RiskGrade 282

ReNeuron Group Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
62.84% above the market average62.84% above the market average62.84% above the market average62.84% above the market average62.84% above the market average
Sector averageSector averageSector averageSector averageSector average
Price Trend
63.43% below the market average63.43% below the market average63.43% below the market average63.43% below the market average63.43% below the market average
43.33% below the sector average43.33% below the sector average43.33% below the sector average43.33% below the sector average43.33% below the sector average
Income Not Available
Growth
1.76% below the market average1.76% below the market average1.76% below the market average1.76% below the market average1.76% below the market average
52.63% below the sector average52.63% below the sector average52.63% below the sector average52.63% below the sector average52.63% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

ReNeuron Group Dividends

No dividends found

Trades for 16-Nov-2018

Time Volume / Share Price
09:05 2,000 @ 61.49p

ReNeuron Group Key Personnel

CFO Michael Hunt
CEO Olav Hellebø

Top of Page